Intrust Bank NA Sells 1,611 Shares of Bristol-Myers Squibb (NYSE:BMY)

Intrust Bank NA cut its holdings in Bristol-Myers Squibb (NYSE:BMY) by 6.8% during the 4th quarter, Holdings Channel reports. The firm owned 21,920 shares of the biopharmaceutical company’s stock after selling 1,611 shares during the period. Intrust Bank NA’s holdings in Bristol-Myers Squibb were worth $1,125,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Mid American Wealth Advisory Group Inc. lifted its stake in Bristol-Myers Squibb by 10.2% in the fourth quarter. Mid American Wealth Advisory Group Inc. now owns 83,155 shares of the biopharmaceutical company’s stock worth $4,050,000 after acquiring an additional 7,688 shares during the period. Choreo LLC boosted its holdings in shares of Bristol-Myers Squibb by 2.9% during the 4th quarter. Choreo LLC now owns 88,442 shares of the biopharmaceutical company’s stock valued at $4,538,000 after buying an additional 2,492 shares in the last quarter. Mather Group LLC. boosted its stake in Bristol-Myers Squibb by 7.1% during the fourth quarter. Mather Group LLC. now owns 25,721 shares of the biopharmaceutical company’s stock worth $1,320,000 after acquiring an additional 1,696 shares in the last quarter. Eagle Wealth Strategies LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $201,000. Finally, Retirement Systems of Alabama lifted its holdings in shares of Bristol-Myers Squibb by 5.0% during the fourth quarter. Retirement Systems of Alabama now owns 1,365,559 shares of the biopharmaceutical company’s stock valued at $70,067,000 after purchasing an additional 65,492 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 1.0 %

Shares of BMY traded down $0.46 during midday trading on Tuesday, hitting $44.18. The stock had a trading volume of 1,802,841 shares, compared to its average volume of 15,792,946. Bristol-Myers Squibb has a 1 year low of $43.97 and a 1 year high of $69.10. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The stock’s 50 day moving average is $50.93 and its 200 day moving average is $51.02. The firm has a market cap of $89.56 billion, a PE ratio of -14.40, a price-to-earnings-growth ratio of 15.47 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.05 earnings per share. As a group, analysts forecast that Bristol-Myers Squibb will post 0.58 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.43%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is presently -77.42%.

Wall Street Analyst Weigh In

BMY has been the subject of a number of analyst reports. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $68.00 to $60.00 in a research report on Wednesday, January 3rd. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Finally, William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.